Crystalline salt forms of SHP2 inhibitor
The development of crystalline anhydrous forms of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate addresses the issues of low crystallinity, purity, and solubility, providing enhanced pharmaceutical efficacy for cancer treatment.
Patent Information
- Application Number
- CN202380027478.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-23
- Filing Date
- 2023-03-20
- Publication Date
- 2024-12-06
AI Technical Summary
Existing forms of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine lack desirable properties such as high crystallinity, high purity, and stability, as well as solubility, which are essential for effective pharmaceutical applications.
Development of crystalline anhydrous forms, particularly the monosuccinate Form 1, characterized by specific PXRD, Raman spectroscopy, and 13C solid-state NMR patterns, enhancing crystallinity, purity, and solubility.
The crystalline anhydrous form of monosuccinate Form 1 exhibits improved crystallinity, purity, and solubility, making it suitable for effective pharmaceutical compositions and treatments, including cancer therapy.
Smart Images

Figure CN119095836A_ABST
Abstract
Description
Background of the Invention
[0002] The present invention relates to crystalline salts of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine, pharmaceutical compositions comprising the crystalline salts, and methods of using the crystalline salts to treat abnormal cell growth, such as cancer, in mammals, particularly humans. One crystalline salt is a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate ("Form 1"), pharmaceutical compositions comprising the succinate Form 1, and methods of using the succinate Form 1 and such compositions to treat abnormal cell growth, such as cancer, in mammals, particularly humans.
[0003] Compound (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine is a SHP2 inhibitor having formula (I):
[0004]
[0005] The preparation of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine is disclosed in International Patent Publication WO 2020 / 201991 (International Application No. PCT / IB2020 / 053019, published on October 8, 2020; see also Example 1), the contents of which are incorporated herein by reference in their entirety.
[0006] The preparation of the hemihydrate crystalline form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine free base Form 1 is disclosed in U.S. Provisional Patent Application 63 / 169,340 (see also Example 2).
[0007] Therefore, there remains a need for improved forms of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine having desirable properties such as high crystallinity, high purity, stability and solubility. SUMMARY OF THE INVENTION
[0009] The present invention provides, in part, crystalline salt forms of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine. The salt forms can be used to treat abnormal cell growth. Pharmaceutical compositions are also provided, which contain the salt forms alone or in combination with additional therapeutic agents. The present invention also provides, in part, methods for preparing such compounds and methods of using the foregoing. This summary is provided to introduce a series of concepts further described in the detailed description below in a simplified form. The summary of the invention is not intended to identify key features or essential features of the subject matter claimed, nor is it intended to be used in isolation as an aid in determining the scope of the subject matter claimed. Each of the embodiments described below can be combined with any other embodiment described herein without being inconsistent with the embodiment with which it is combined.
[0010] One embodiment of the present invention provides, in part, a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1. The succinate Form 1 compound can be used to treat abnormal cell growth. Also provided are pharmaceutical compositions comprising the succinate Form 1 alone or in combination with an additional therapeutic agent. The present invention also provides, in part, methods for preparing such compounds and methods of using the foregoing.
[0011] According to an embodiment of the present invention, a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate salt Form 1 is provided. The succinate salt Form 1 can be characterized by powder X-ray diffraction ("PXRD") (2θ), Raman spectroscopy (cm -1 ) and / or 13 C solid-state nuclear magnetic resonance ("NMR") (ppm) characterization.
[0012] According to another embodiment of the present invention, there is provided a pharmaceutical composition comprising a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1.
[0013] According to another embodiment of the present invention, there is provided a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 for use as a medicament.
[0014] According to another embodiment of the present invention, there is provided a method for treating abnormal cell growth comprising administering an effective amount of a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1.
[0015] According to another embodiment of the present invention, there is provided a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 for use in a method for treating abnormal cell growth.
[0016] According to another embodiment of the present invention, there is provided a use of a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1 for the preparation of a medicament.
[0017] Described below are embodiments of the present invention, starting with Embodiment 1 (E1).
[0018] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
[0019] BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Shown is the PXRD pattern of the crystalline anhydrous form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine monosuccinate salt Form 1.
[0021] Figure 2 The crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate Form 1 is shown. 13 C ssNMR spectrum.
[0022] Figure 3 Shown is the Raman spectrum of the crystalline anhydrous form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine monosuccinate salt Form 1.
[0023] Figure 4Shown is a PXRD pattern of a crystalline form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine phosphate (Pattern 1).
[0024] Figure 5 Shown is a PXRD pattern of a crystalline form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine phosphate (Pattern 2).
[0025] Figure 6 Shown is a PXRD pattern of a crystalline form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine fumarate.
[0026] Figure 7 Shown is a PXRD pattern of a crystalline form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine tartrate salt.
[0027] Figure 8 Shown is a PXRD pattern of a crystalline form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine hydrochloride. DETAILED DESCRIPTION OF THE INVENTION
[0029] The present invention can be more easily understood by referring to the following detailed description of embodiments of the present invention and the examples included therein. It should be understood that the present invention is not limited to specific synthetic preparation methods, which can certainly vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to be restrictive.
[0030] A crystalline anhydrous form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine monosuccinate salt Form 1 has been discovered. Figure 1 The PXRD pattern of the succinate salt Form 1 is shown. Figure 2 Showing succinate form 1 13 CssNMR spectrum. Figure 3 The Raman spectrum of the succinate salt form 1 is shown. The peak positions (° 2θ), wavenumbers (cm -1) and resonance values (ppm) should be substantially the same. As used herein, the term "substantially the same" means taking into account the typical variability of a particular method. For example, with reference to X-ray diffraction peak positions, the term "substantially the same" means taking into account the typical variability of peak positions and intensities. Those skilled in the art will understand that peak positions (2θ) will show some variability, typically up to ±0.2°. In addition, those skilled in the art will understand that relative peak intensities will show inter-device variability, as well as variability due to crystallinity, preferred orientation, prepared sample surface, and other factors known to those skilled in the art, and should be taken only as qualitative measurements. For wave number values, those skilled in the art will understand that the wave number values will show some variability, typically up to ±2 cm -1 For the resonance values, those skilled in the art will appreciate that the wavenumber values will show some variability, typically as much as ±0.2 ppm.
[0031] E1 A crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate.
[0032] The compound of E2 E1 is characterized in that: (1) the powder X-ray diffraction pattern contains peaks at the following 2θ values: 19.7, 24.3, 9.3 and 16.6±0.2°2θ; (2) the Raman spectrum contains the following wavenumbers (cm -1 ) Value: 1041 and 1217cm -1 ±2cm -1 or (3) 13 The C solid state NMR spectrum contained the following resonance (ppm) values: 179.0 ppm ± 0.2 ppm.
[0033] E3 A compound of E1 or E2 characterized by two of the following: (1) a powder X-ray diffraction pattern comprising peaks at the following 2θ values: 19.7, 24.3, 9.3 and 16.6 ± 0.2° 2θ; (2) a Raman spectrum comprising the following wavenumbers: 1041 and 1217 cm -1 ±2cm -1 or (3) 13 The C solid state NMR spectrum contained the following resonance values: 179.0 ppm ± 0.2 ppm.
[0034] E4 The compound of any one of embodiments E1 to E3, characterized in that: (1) the powder X-ray diffraction pattern comprises peaks at the following 2θ values: 19.7, 24.3, 9.3 and 16.6±0.2° 2θ; (2) the Raman spectrum comprises the following wavenumbers: 1041 and 1217 cm -1 ±2cm -1 ; and (3)13 The C solid state NMR spectrum contained the following resonance values: 179.0 ppm ± 0.2 ppm.
[0035] E5 The compound of any one of Embodiments E1 to E4, which has a powder X-ray diffraction pattern comprising peaks at the following 2θ values: 19.7, 24.3, 9.3 and 16.6±0.2° 2θ.
[0036] E6 The compound of embodiment E6, whose powder X-ray diffraction pattern further comprises a peak at the following 2θ value: 9.0±0.2° 2θ.
[0037] E7 The compound of any one of embodiments E5 to E6, whose powder X-ray diffraction pattern further comprises a peak at the following 2θ value: 28.0±0.2° 2θ.
[0038] E8 The compound of any one of embodiments E5 to E7, which has a powder X-ray diffraction pattern further comprising a peak at the following 2θ value: 18.8±0.2° 2θ.
[0039] E9 The compound of any one of embodiments E5 to E8, whose powder X-ray diffraction pattern further comprises a peak at the following 2θ value: 15.7±0.2° 2θ.
[0040] E10 The compound of any one of embodiments E5 to E9, which has a powder X-ray diffraction pattern further comprising a peak at the following 2θ value: 12.1±0.2° 2θ.
[0041] E11 The compound of any one of Embodiments E5 to E10, which has a powder X-ray diffraction pattern further comprising peaks at the following 2θ values: 4.5, 8.4, 13.9, 16.5, 17.1, 17.6, 17.8, 18.0, 19.9, 21.1, 21.3, 21.7, 21.8, 22.8, 23.0, 23.5, 24.0, 24.4, 25.6, 26.0, 26.2, 26.9, 28.3, 28.7, 29.1, 29.9, 30.5, 31.7, 31.8, 32.8, 33.4, 33.8, 35.0, 35.9, 36.1, 36.4, 36.8, 37.1, 38.0, 38.7, and 39.3 ± 0.2 ° 2θ.
[0042] E12 A compound according to any one of embodiments E5 to E11, whose PXRD is substantially the same as Figure 1 same.
[0043] E13 A compound according to any one of embodiments E1 to E12, whose Raman spectrum comprises the following wavenumbers (cm -1 ) Value: 1041 and 1217cm -1 ±2cm-1 .
[0044] E14 A compound according to embodiment E13, whose Raman spectrum further comprises the following wavenumbers (cm -1 ) Values: 1026 and 1555cm -1 ±2cm -1 .
[0045] E15 A compound according to any one of embodiments E13 to E14, whose Raman spectrum is substantially Figure 2 same.
[0046] E16 A compound according to any one of embodiments E1 to E15, which 13 The C solid state NMR spectrum contained the following resonance (ppm) values: 179.0 ppm ± 0.2 ppm.
[0047] E17 A compound according to any one of embodiments E1 to E16, which 13 The C solid state NMR spectrum further contained the following resonance (ppm) values: 46.4 ppm ± 0.2 ppm.
[0048] E18 A compound according to any one of embodiments E1 to E17, which 13 The C solid state NMR spectrum further contained the following resonance (ppm) values: 38.0 ppm ± 0.2 ppm.
[0049] E19 A compound according to any one of embodiments E1 to E18, which 13 The C solid state NMR spectrum further contained the following resonance (ppm) values: 141.7 ppm ± 0.2 ppm.
[0050] E20 A compound according to any one of embodiments E16 to E19, which 13 The C solid state NMR spectrum further contained the following resonance (ppm) values: 27.1 ppm ± 0.2 ppm.
[0051] E21 A compound according to any one of embodiments E16 to E20, which 13 C solid-state NMR spectroscopy is essentially the same as Figure 3 same.
[0052] E22 A compound according to any one of Embodiments E1 to E21 which is substantially pure and free from other forms.
[0053] E23 The compound of any one of Embodiments E1 to E22, wherein the succinate salt form 1 is greater than 95% substantially pure.
[0054] E24 The compound of any one of Embodiments E1 to E23, wherein the succinate salt Form 1 is greater than 97% substantially pure.
[0055] E25 The compound of any one of Embodiments E1 to E24, wherein the succinate salt form 1 is greater than 99% substantially pure.
[0056] The present invention also encompasses pharmaceutical compositions comprising the succinate salt form 1. Typical formulations or compositions are prepared by mixing the compounds described herein with a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail, for example, in Ansel, Howard C., et al., Ansel' sPharmaceuticalDosageForms and DrugDeliverySystems. Philadelphia: Lippincott, Williams and Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice iceofPharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005, the disclosure of which is incorporated herein by reference.
[0057] E26 A pharmaceutical composition comprising a compound according to any one of embodiments E1 to E25 and at least one pharmaceutically acceptable excipient.
[0058] The compositions of the present invention can be in various forms. These forms include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersants or suspensions, tablets, capsules, pills, powders, liposomes and suppositories. The form depends on the intended mode of administration and therapeutic application.
[0059] Typical compositions are in the form of injectable or infusible solutions, such as compositions similar to those commonly used for passive immunization of humans with antibodies. One mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In another embodiment, the compound is administered by intravenous infusion or injection. In yet another embodiment, the compound is administered by intramuscular or subcutaneous injection.
[0060] Oral administration of solid dosage forms can be, for example, presented as discrete units, such as hard or soft capsules, pills, cachets, lozenges or tablets, each containing a predetermined amount of at least one compound of the present invention. In another embodiment, oral administration can be in the form of a powder or granules. In another embodiment, the oral dosage form is sublingual, such as, for example, a lozenge. In such solid dosage forms, the compounds of the present invention are typically combined with one or more adjuvants. Such capsules or tablets may contain controlled release formulations. In the case of capsules, tablets and pills, the dosage form may also contain a buffer or may be prepared with an enteric coating.
[0061] Other excipients and modes of administration known in the pharmaceutical field may also be used. The pharmaceutical compositions of the present invention may be prepared by any of the well-known pharmaceutical techniques, such as effective formulations and administration procedures. The above considerations regarding effective formulations and administration procedures are well known in the art and are described in standard textbooks. The formulation of drugs is discussed in, for example, Ansel (supra) and Gennaro (supra).
[0062] The present invention also encompasses a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 for use as a medicament.
[0063] E27 A compound according to any one of embodiments E1 to E26 for use as a medicament.
[0064] The present invention also encompasses methods of treatment comprising administering a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 according to any one of the embodiments described herein. In particular, the methods of treatment are for a subject in need thereof. In most embodiments, the subject is a mammal. In some embodiments, the subject is a human.
[0065] E28 A method of treating abnormal cell growth, comprising administering to a subject in need thereof an effective amount of a therapeutically effective amount of a compound of any one of embodiments E1 to E26.
[0066] E29 A method of treating abnormal cell growth in a mammal, comprising administering to the mammal an effective amount of a therapeutically effective amount of a compound of any one of embodiments E1 to E26.
[0067] E30 The method of embodiment E29, wherein the mammal is a human.
[0068] E31 The method of any one of embodiments E28 to E30, wherein the abnormal cell growth is cancer.
[0069] The present invention also encompasses a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 for use in treating abnormal cell growth.
[0070] E32 A compound according to any one of embodiments E1 to E26 for use in treating abnormal cell growth.
[0071] E33 A compound according to any one of embodiments E1 to E26 for use in treating abnormal cell growth in a mammal.
[0072] E34 A compound according to any one of embodiments E1 to E26 for use in treating abnormal cell growth in a human.
[0073] E35 The compound of any one of embodiments E32 to E34, wherein the abnormal cell growth is cancer.
[0074] The present invention also encompasses the use of the crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1 for the preparation of a medicament.
[0075] E36 Use of a compound according to any one of embodiments E1 to E26 for the preparation of a medicament.
[0076] E37 Use of a compound according to any one of embodiments E1 to E26 for the preparation of a medicament for the treatment of abnormal cell growth.
[0077] E38 Use of a compound according to any one of embodiments E1 to E26 for the preparation of a medicament for treating abnormal cell growth in a mammal.
[0078] E39 Use of a compound according to any one of embodiments E1 to E26 for the preparation of a medicament for the treatment of abnormal cell growth in a human.
[0079] E40 The use of any one of embodiments E36 to E39, wherein the abnormal cell growth is cancer.
[0080] In the common embodiment of the method provided herein, abnormal cell growth is cancer. As used herein, "cancer" refers to a physiological condition characterized by abnormal or unregulated cell growth in mammals. Cancer includes solid tumors named after the type of cells that form them, cancers of the blood, bone marrow or lymphatic system. Examples of solid tumors include sarcomas and carcinomas. Hematological cancers include but are not limited to leukemias, lymphomas and myelomas. Cancer also includes primary cancers originating from a specific part of the body, metastatic cancers that spread from its starting position to other parts of the body, recurrence of the initial primary cancer after remission and the second primary cancer as a new primary cancer of an individual, the individual having a previous cancer history different from the type of the latter cancer.
[0081] The provided methods produce one or more of the following effects: (1) inhibiting cancer cell proliferation; (2) inhibiting cancer cell invasion; (3) inducing cancer cell apoptosis; (4) inhibiting cancer cell metastasis; or (5) inhibiting angiogenesis.
[0082] Treatment achieved by the crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1 is defined by reference to any of the following: partial response (PR), complete response (CR), overall response (OR), progression-free survival (PFS), disease-free survival (DFS), and overall survival (OS). PFS (also known as "time to tumor progression") indicates the length of time that cancer does not grow during and after treatment, and includes the amount of time a patient experiences a CR or PR and the amount of time a patient experiences stable disease (SD). DFS refers to the length of time a patient remains disease-free during and after treatment. OS refers to the extension of the life expectancy of an untreated or untreated subject or patient compared to an untreated or untreated subject or patient. In some embodiments, the response to the combination of the present invention is any one of PR, CR, PFS, DFS, OR, or OS assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response criteria.
[0083] E41 The method, compound or use of any one of embodiments E31, E35 or E40, wherein the cancer is selected from the group consisting of melanoma, juvenile myelomonocytic leukemia, neuroblastoma, Philadelphia chromosome positive chronic myeloid leukemia, Philadelphia chromosome positive acute lymphoblastic leukemia, acute myeloid leukemia, myeloproliferative neoplasms (such as polycythemia vera, essential thrombocythemia and primary myelofibrosis), breast cancer, lung cancer, liver cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma, glioblastoma, anaplastic large cell lymphoma, thyroid cancer and spitzoid tumors.
[0084] E42 The method, compound or use of embodiment E41, wherein the cancer is melanoma.
[0085] E43 The method, compound or use of embodiment E41, wherein the cancer is juvenile myelomonocytic leukemia.
[0086] E44 The method, compound or use of embodiment E41, wherein the cancer is neuroblastoma.
[0087] E45 The method, compound or use of embodiment E41, wherein the cancer is Philadelphia chromosome-positive chronic myeloid leukemia.
[0088] E46 The method, compound or use of embodiment E41, wherein the cancer is Philadelphia chromosome-positive acute lymphoblastic leukemia.
[0089] E47 The method, compound or use of embodiment E41, wherein the cancer is acute myeloid leukemia.
[0090] E48 The method, compound or use of embodiment E41, wherein the cancer is a myeloproliferative neoplasm (such as polycythemia vera, essential thrombocythemia and primary myelofibrosis).
[0091] E49 The method, compound or use of embodiment E48, wherein the cancer is polycythemia vera.
[0092] E50 The method, compound or use of embodiment E48, wherein the cancer is essential thrombocythaemia.
[0093] E51 The method, compound or use of embodiment E48, wherein the cancer is primary myelofibrosis.
[0094] E52 The method, compound or use of embodiment E41, wherein the cancer is breast cancer.
[0095] E53 The method, compound or use of embodiment E41, wherein the cancer is lung cancer.
[0096] E54 The method, compound or use of embodiment E41, wherein the cancer is liver cancer.
[0097] E55 The method, compound or use of embodiment E41, wherein the cancer is colorectal cancer.
[0098] E56 The method, compound or use of embodiment E41, wherein the cancer is esophageal cancer.
[0099] E57 The method, compound or use of embodiment E41, wherein the cancer is gastric cancer.
[0100] E58 The method, compound or use of embodiment E41, wherein the cancer is head and neck squamous cell carcinoma.
[0101] E59 The method, compound or use of embodiment E41, wherein the cancer is glioblastoma.
[0102] E60 The method, compound or use of embodiment E41, wherein the cancer is anaplastic large cell lymphoma.
[0103] E61 The method, compound or use of embodiment E41, wherein the cancer is thyroid cancer.
[0104] E62 The method, compound or use of embodiment E41, wherein the cancer is a Spitzoid tumor.
[0105] E63 The method, compound or use of any one of embodiments E31, E35 or E40, wherein the cancer is selected from the group consisting of non-small cell lung cancer ("NSCLC"), colon cancer, esophageal cancer, rectal cancer, juvenile myelomonocytic leukemia ("JMML"), breast cancer, melanoma and pancreatic cancer.
[0106] E64 The method, compound or use of embodiment E63, wherein the cancer is NSCLC.
[0107] E65 The method, compound or use of embodiment E63, wherein the cancer is colon cancer.
[0108] E66 The method, compound or use of embodiment E63, wherein the cancer is esophageal cancer.
[0109] E67 The method, compound or use of embodiment E63, wherein the cancer is rectal cancer.
[0110] E68 The method, compound or use of embodiment E63, wherein the cancer is JMML.
[0111] E69 The method, compound or use of embodiment E63, wherein the cancer is breast cancer.
[0112] E70 The method, compound or use of embodiment E63, wherein the cancer is melanoma.
[0113] E71 The method, compound or use of embodiment E63, wherein the cancer is pancreatic cancer.
[0114] E72 The method, compound or use of any one of embodiments E31, E35 or E40, wherein the cancer is selected from the group consisting of ALK-positive NSCLC, ROS1-positive NSCLC, BRAF V600E mutant colorectal cancer, RAS mutant solid tumors, NF1 mutant solid tumors and BRAF class 3 mutant solid tumors.
[0115] E73 The method, compound or use of embodiment E72, wherein the cancer is ALK-positive NSCLC.
[0116] E74 The method, compound or use of embodiment E73, wherein the cancer treated has been previously treated with lorlatinib and previously treated with platinum-based chemotherapy.
[0117] E75 The method, compound or use of embodiment E73, wherein the cancer treated is previously treated with lorlatinib and not previously treated with platinum-based chemotherapy.
[0118] E76 The method, compound or use of embodiment E73, wherein the cancer treated has not been previously treated with lorlatinib.
[0119] E77 The method, compound or use of embodiment E72, wherein the cancer is ROS1 -positive NSCLC.
[0120] E78 The method, compound or use of embodiment E72, wherein the cancer is BRAF V600E mutant colorectal cancer.
[0121] E79 The method, compound or use of embodiment E78, wherein the cancer treated is resistant to treatment with a BRAF inhibitor ("BRAFi") plus an epidermal growth factor receptor inhibitor ("EGFRi").
[0122] E80 The method, compound or use of embodiment E78, wherein the cancer treated is refractory to BRAFi plus EGFRi treatment.
[0123] E81 The method, compound or use of embodiment E78, wherein the cancer treated has not been previously treated with BRAFi plus EGFRi.
[0124] E82 The method, compound or use of embodiment E72, wherein the cancer is a RAS mutant solid tumor.
[0125] E83 The method, compound or use of embodiment E81, wherein the cancer being treated has been previously treated with standard of care.
[0126] E84 The method, compound or use of embodiment E72, wherein the cancer is an NF1 mutant solid tumor.
[0127] E85 The method, compound or use of embodiment E84, wherein the cancer being treated has been previously treated with standard of care.
[0128] E86 The method, compound or use of embodiment E72, wherein the cancer is a BRAF class 3 mutant solid tumor.
[0129] E87 The method, compound or use of embodiment E86, wherein the BRAF class 3 mutation is selected from one or more of the following amino acid substitutions in human BRAF: D287H; P367R; V459L; G466V; G466E; G466A; S467L; G469E; N581S; N581I; D594N; D594G; D594A; D594H; F595L; G596D; G596R and A762E.
[0130] E88 The method, compound or use of embodiment E86 or E87, wherein the cancer being treated has been previously treated with standard of care.
[0131] E89 The method, compound or use of embodiment E31, E35 or E40, wherein the cancer treated is a KRAS mutant cancer.
[0132] E90 The method, compound or use of embodiment E89, wherein the cancer is selected from KRAS G12A Mutation, KRAS G12C Mutation, KRAS G12D Mutation, KRAS G12F Mutation, KRAS G12I Mutation, KRAS G12L Mutation, KRAS G12R Mutation, KRAS G12S Mutation, KRAS G12V Mutations and KRAS G12Y mutation.
[0133] The present invention also encompasses the use of the crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1 in combination with an additional therapeutic compound.
[0134] Two or more compounds "combination" administration refers to the administration time of all compounds is close enough to affect the treatment of the subject. According to the treatment plan, two or more compounds can be administered simultaneously or sequentially, by the same or different administration routes, according to the same or different administration schedules and with or without specific time limits. In addition, simultaneous administration can be performed by mixing the compounds before administration or by administering the compounds as a separate dosage form at the same time point but at the same or different administration sites. The example of "combination" includes but is not limited to "parallel administration", "co-administration", "simultaneous administration", "sequential administration" and "simultaneous administration".
[0135] The crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1 and one or more additional therapeutic agents can be administered as a fixed or non-fixed combination of active ingredients. The term "fixed combination" means that the crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1 and one or more therapeutic agents are both administered to a subject simultaneously in a single composition or dose. The term "non-fixed combination" means that the crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1 and one or more therapeutic agents are formulated as separate compositions or dosages so that they can be administered to a subject in need thereof simultaneously or at different times with variable intervals of time, wherein such administration provides effective levels of the two or more compounds in the body of the subject.
[0136] E91 The method, compound or use of any one of embodiments E27 to E90, wherein the compound of any one of embodiments E1 to E26 is used in combination with an additional therapeutic compound.
[0137] E92 The method, compound or use of embodiment E91, wherein the additional therapeutic compound is selected from the group consisting of lorlatinib, binimetinib, cetuximab and encorafenib.
[0138] E93 The method, compound or use of embodiment E91 or E92, wherein the additional therapeutic compound is lorlatinib.
[0139] E94 The method, compound or use of embodiment E91 or E92, wherein the additional therapeutic compound is bemetinib.
[0140] E95 The method, compound or use of embodiment E91 or E92, wherein the additional therapeutic compound is cetuximab and enemafenib.
[0141] E96 The method, compound or use of embodiment E91 or E92, wherein the additional therapeutic compound is cetuximab.
[0142] E97 The method, compound or use of embodiment E91 or E92, wherein the additional therapeutic compound is contrafenib.
[0143] definition
[0144] As used herein, the singular forms "a", "an" and "the" include plural referents unless otherwise specified. For example, "a" substituent includes one or more substituents.
[0145] The term "about" refers to a value having an acceptable standard of error from the mean value as considered by one of ordinary skill in the art.
[0146] As used herein, the term "crystalline" refers to having a regularly repeating arrangement of molecules or external surface planes. Crystal forms may differ in thermodynamic stability, physical parameters, x-ray structure, and method of preparation.
[0147] The invention described herein can be suitably practiced in the absence of any element not specifically disclosed herein. Thus, for example, in each instance herein, any one of the terms "comprising," "consisting essentially of," and "consisting of" can be replaced by any one of the other two terms.
[0148] The term "substantially pure" means that a particular crystalline form comprises less than 10%, preferably less than 5%, preferably less than 3%, preferably less than 1% by weight of any other physical form of the compound.
[0149] As used herein, "pharmaceutical composition" refers to a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 according to any one of the embodiments described herein as an active ingredient, and at least one pharmaceutically acceptable excipient.
[0150] As used herein, "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
[0151] The term "excipient" is used herein to describe any ingredient other than the crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1. The choice of excipient will depend largely on factors such as the mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form. Excipients include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, carriers, diluents, and the like, which are physiologically compatible. Examples of excipients include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, and combinations thereof, and may include isotonic agents in the composition, for example, sugars, sodium chloride, or polyols such as mannitol or sorbitol. Examples of excipients also include various organic solvents (such as hydrates and solvates). If desired, the pharmaceutical composition can contain additional excipients, such as flavoring agents, binders (binder / binding agent), lubricants, disintegrants, sweeteners or flavoring agents, colorants or dyes, etc. For example, for oral administration, tablets containing various excipients (such as citric acid) can be used together with various disintegrants (such as starch, alginic acid and some complex silicates) and binders (such as sucrose, gelatin and gum arabic). The example of excipient includes calcium carbonate, calcium phosphate, various sugars and various types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols without limitation. In addition, lubricants such as magnesium stearate, sodium lauryl sulfate and talcum powder are commonly used for tableting purposes. Solid compositions of similar types can also be used with soft and hard filled gelatin capsules. Therefore, the non-limiting examples of excipients also include lactose (lactose / milk sugar) and high molecular weight polyethylene glycol. When aqueous suspensions or elixirs are desired for oral administration, the active compound therein may be combined with various sweetening or flavoring agents, colorants or dyes and emulsifying or suspending agents, if desired, and with additional excipients such as water, ethanol, propylene glycol, glycerol, or combinations thereof.
[0152] Examples of excipients also include pharmaceutically acceptable substances such as wetting agents or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the compound.
[0153] As used herein, an "effective dose" or "effective amount" of a drug, compound, or pharmaceutical composition is an amount sufficient to affect any one or more beneficial or desired symptoms (including biochemical, histological, and / or behavioral symptoms) of a disease, its complications, and intermediate pathological phenotypes exhibited during the development of the disease. For therapeutic uses, a "therapeutically effective amount" refers to the amount of the compound administered that will alleviate to some extent one or more of the symptoms of the disorder being treated. With reference to cancer treatment, a therapeutically effective amount refers to an amount that has the following effects: (1) reducing tumor size; (2) inhibiting (i.e., slowing to some extent, preferably stopping) tumor metastasis; (3) inhibiting (i.e., slowing to some extent, preferably stopping) tumor growth or tumor invasion; (4) alleviating to some extent (or preferably, eliminating) one or more signs or symptoms associated with cancer; (5) reducing the dose of other drugs required to treat the disease; and / or (6) enhancing the effect of another drug; and / or (7) delaying the progression of the disease in a patient.
[0154] As used herein, "mammal" refers to a warm-blooded animal that suffers from or is at risk of suffering from a disease described herein, and includes, but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans.
[0155] As used herein, "subject" refers to a human or animal subject. In certain embodiments, the subject is a mammal. In certain preferred embodiments, the subject is a human.
[0156] As used herein, "Treat" or "treating" refers to administering the crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 to a subject suffering from the condition to be treated to achieve at least one positive therapeutic effect. For example, treating cancer refers to administering a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 to a subject having or diagnosed with cancer to achieve at least one positive therapeutic effect, such as, for example, reducing the number of cancer cells, reducing tumor size, reducing the rate of cancer cell infiltration into peripheral organs or reducing the rate of tumor metastasis or tumor growth, reversing, alleviating, inhibiting the progression of a disorder or condition to which this term applies, or preventing a disorder or condition to which this term applies, or one or more symptoms of such a disorder or condition. As used herein, unless otherwise indicated, the term "treatment" refers to the act of treating as "treating" as defined immediately above. The term "treatment" also includes adjuvant and neoadjuvant treatment of a subject. Example
[0157] The examples and preparations provided below further illustrate and illustrate specific aspects and embodiments of the present invention. It should be understood that the scope of the following examples does not limit the scope of the present invention. The compounds and intermediates described herein are named using the naming conventions provided by ChemDraw Professional version 19.0.0.22 (Perkin Elmer Informatics, Inc., Waltham, Mass.).
[0158] Example 1
[0159] Amorphous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-di Hydrospiro[indene-2,4'-piperidinyl]-1-amine free base
[0160] (R)-N-((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfinamide (20 mg, 0.037 mmol) was diluted with dioxane (1 mL) followed by the addition of HCl (92 μL, 0.37 mmol). After stirring for 30 minutes, the reaction was diluted with dichloromethane ("DCM") and saturated aqueous sodium bicarbonate. After stirring the mixture for 10 minutes, the layers were separated and the DCM was dried over MgSO, filtered and concentrated. The material was purified on silica gel eluting with 20% methanol / ethyl acetate to afford amorphous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine free base (15 mg, 0.034 mmol, 93% yield). 1 H NMR (400MHz, CDCl3) δ8.2 (s, 1H), 7.76 (d, 1H, J = 5.2Hz), 7.2-7.35 (m, 4H), 6.15 (d, 1H, J = 5.2Hz), 4.92 (br, 2H), 4.78 (br,1H),4.01(s,1H),3.37(m,2H),3.14(d,1H,J=15.6Hz),2.78(d,1H,J=15.6),1.3-1.91(m,7H); m / z(esi / APCI)M + 1=440.1.
[0161] Example 2
[0162] Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydro Spiro[indene-2,4'-piperidinyl]-1-amine free base hemihydrate (Form 1)
[0163] At 20-30°C, (S)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine dihydrochloride (3.89 Kg) and 3,6-dibromo-1,2,4-triazine (3.71 Kg) were reacted with triethylamine (6.45 Kg) in 1,4-dioxane (34.3 Kg) to obtain (S)-1'-(6-bromo-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine in situ. At 20-30° C., (S)-1′-(6-bromo-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine was reacted with sodium 2-amino-3-chloropyridine-4-thiolate (3.08 Kg) and triethylamine (6.45 Kg) in 1,4-dioxane (2.05 Kg), and the mixture was heated to 70-75° C. for about 12.5 hours to obtain (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine. The mixture was cooled to about 15-30° C. and heated at 15-30° C. (1.95Kg) is added to the reaction, and stirred for about 1 hour, and the slurry is filtered and rinsed with 1,4-dioxane. Solvent exchange is carried out to replace 1,4-dioxane with tetrahydrofuran. Crude (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)sulfenyl)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine is purified by silica gel (pretreated with isopropanol) chromatography using a mixture of dichloromethane, methanol, ethanol, n-hexane and triethylamine as eluent. After chromatography, at 15-30°C, the product (1.57Kg) is merged with methanol (24.0Kg) and water (1.6Kg). The mixture is heated to 40°C and reduced pressure is applied until about 22-25L of mixture remains. At 15-30°C, methanol (24.0 Kg) and water (1.6 Kg) were added. The mixture was heated to 40°C and reduced pressure was applied until about 22-25 L of the mixture remained. At 15-30°C, water (15.70 Kg) was added. The mixture was stirred at 15-25°C for 12 hours to induce crystallization. The product was collected by filtration, and the filter cake was rinsed with a mixture of methanol (3.7 Kg) and water (1.6 Kg) to obtain purified crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine free base hemihydrate (Form 1) (1.39 Kg).
[0164] Powder X-ray diffraction analysis was performed using a Bruker AXSD8 Endeavor diffractometer equipped with a copper (Cu) radiation source. The divergence slit was set to 15 mm with continuous illumination. The diffracted radiation was detected using a PSD-Lynx Eye detector with the detector PSD opening set to 2.99 degrees. The X-ray tube voltage and current were set to 40 kV and 40 mA, respectively. In the θ-θ goniometer, the Cu wavelength was stepped from 3.0 to 40.0 degrees 2θ using a step size of 0.00998 degrees and a step time of 1.0 seconds. Data were collected under . The anti-scatter screen was set to a fixed distance of 3.0 mm. The sample was rotated at 15 / min during collection. The sample was prepared by placing it in a low silicon content background sample holder and rotated during collection. Data were collected using BrukerDIFFRAC Plus software and analyzed by EVA diffract plus software. The PXRD data file was not processed before peak search. A preliminary peak assignment was made using the selected peak with a threshold of 1 using the peak search algorithm in the EVA software. To ensure validity, adjustments were made manually; the output of the automatic assignment was visually inspected and the peak position was adjusted to the peak maximum. Peaks with a relative intensity ≥3% were typically selected. Peaks that were not resolved or consistent with noise were typically not selected. The typical error associated with the PXRD peak position specified by USP is at most + / -0.2°2θ (USP-941).
[0165] The PXRD peak list (2θ°) and relative intensity data for the compound of Example 2, free base hemihydrate Form 1 are provided in Table 1 below:
[0166] Table 1
[0167] Angle (2θ°) ±0.2°2θ Relative strength (%) Angle (2θ°) ±0.2°2θ Relative strength (%) 5.4 6.8 26.8 13.9 10.9 60.1 27.1 51.2 12.1 5.2 27.3 50.9 13.5 3.4 27.8 11.6 14.0 40.2 28.2 71.3 15.4 54.9 29.3 16.6 15.5 44.5 29.5 41.5 16.0 61.8 30.0 5.6 16.4 23.1 31.5 12.6 17.2 49.8 31.9 3.9 17.7 16.5 32.2 9.9 19.0 19.1 33.2 12.1 19.3 45.5 33.3 10.0 19.6 41.2 33.9 4.5 19.7 41.5 34.1 5.7 20.5 39.6 34.7 7.4 21.8 33.4 35.2 11.7 22.2 15.0 35.4 12.6 22.5 100.0 36.1 5.9 23.5 5.5 36.9 3.3 24.3 18.4 37.2 5.0 25.1 68.5 37.5 3.2 25.4 5.3 38.0 5.6 25.7 12.5 38.6 3.5 26.0 7.2 39.0 4.5
[0168] The characteristic PXRD peak list (2θ°) and relative intensity data for the compound of Example 2, free base hemihydrate Form 1 are provided in Table 2 below:
[0169] Table 2
[0170]
[0171]
[0172] Solid-state NMR ("ssNMR") analyses were performed on a cross-polarization magic angle spinning ("CPMAS") probe mounted on a Bruker-BioSpin Avance III 500 MHz ( 1The material was packed in a 4 mm ZrO2 rotor. A magic angle spinning rate of 14.0 kHz was used. Spectra were collected at ambient temperature (temperature was not controlled).
[0173] Acquisition of proton-decoupled CPMAS experiments 13 C ssNMR spectra. A phase-modulated proton decoupling field of 80-100 kHz was applied during spectral acquisition. The cross-polarization contact time was set to 2 milliseconds and the recycle delay was set to 11.4 seconds. The number of scans was adjusted to obtain a sufficient signal-to-noise ratio. 13 C chemical shift scaling using 13 C CPMAS experiments were referenced to an external standard of crystalline adamantane, whose upfield resonance was set to 29.5 ppm.
[0174] Automated peak picking was performed using Bruker-BioSpin TopSpin version 3.6 software. Typically, a threshold of 5% relative intensity was used for preliminary peak selection. The output of automated peak picking was visually inspected to ensure validity and manual adjustments were made if necessary. Although specific solid-state NMR peaks are reported herein, there does exist a range of these peaks due to differences in instrumentation, samples, and sample preparation. This is common practice in solid-state NMR techniques due to the inherent variability in peak positions. For crystalline solids, 13 Typical variability in C chemical shift x-axis values is on the order of plus or minus 0.2 ppm. The solid-state NMR peak heights reported herein are relative intensities. Solid-state NMR intensities can vary depending on the actual setup of the CPMAS experimental parameters and the thermal history of the sample.
[0175] For the crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine free base hemihydrate (Form 1), five characteristic peaks were identified: 13 The C chemical shifts are at 44.4, 47.7, 149.2, 36.6, and 26.9 ± 0.2 ppm. This characteristic peak was chosen because it has high intensity, narrow peak shape, is unique to the solid form, and is likely not to be obscured in the drug spectra.
[0176] Example 2, Free Base Hemihydrate Form 1 13 The C ssNMR spectra (ppm) are provided in Table 3 below:
[0177] Table 3
[0178] <![CDATA[ 13 C chemical shift (ppm) ±0.2ppm]]> Relative strength (%) 26.9 51 33.8 39 35.0 59 36.6 37 39.0 82 39.4 67 40.2 67 41.3 38 43.4 81 44.4 74 47.7 63 66.0 49 68.9 38 109.0 93 124.5 100 127.0 41 127.9 70 128.9 51 129.8 43 139.7 88 140.9 48 145.1 57 145.4 79 146.5 39 149.2 49 154.5 48 155.9 64 158.9 38
[0179] Raman spectra were collected using a Thermo Scientific iS50 FT-Raman accessory connected to a FT-IR bench. A CaF2 beam splitter was used in the FT-Raman setup. The spectrometer was equipped with a 1064 nm diode laser and a room temperature InGaAs detector. Prior to data collection, instrument performance and calibration verification was performed using polystyrene. During data collection, samples were analyzed as tablets in glass NMR tubes or samples were kept static in a suitable sample holder. Spectra were collected using laser powers between 0.1 and 0.5 W and 512 co-added scans. The collection range was 3700 to 100 cm -1 Use 2cm -1 API spectra were recorded at 100 Å resolution and Happ-Genzel apodization was used for all spectra. Multiple spectra were recorded and the reported spectra represent two points.
[0180] Before picking the peak, the intensity scale was normalized to 1. The peaks were manually determined using Thermo Nicolet Omnic 9.7.46 software. The peak position was picked at the peak maximum and was determined as a peak only when there was a slope on each side; the shoulder of the peak was not included. For the solvent-free (neat) free base hemihydrate form 1, an absolute threshold of 0.006 and a sensitivity of 75 were used during peak picking. The peak position was rounded to the nearest integer using standard operation (0.5 rounding, 0.4 rounding). Peaks with standardized peak intensities between (1-0.75), (0.74-0.30), and (0.29-0) were marked as strong, medium, and weak, respectively.
[0181] Characteristic peaks of the free base hemihydrate Form 1 were selected based on intensity as well as peak position. Free base hemihydrate Form 1 was compared to placebo and active blends (6 and 15% DL) to ensure the uniqueness of free base hemihydrate Form 1.
[0182] FT-Raman spectrum peak list of the compound of Example 2, free base hemihydrate form 1 (cm -1 ) and normalized intensity data are provided in Table 4 below:
[0183] Table 4
[0184]
[0185]
[0186] Characteristic FT-Raman spectral peak list of the compound of Example 2, free base hemihydrate form 1 (cm -1 ) and normalized intensity data are provided in Table 5 below:
[0187] Table 5
[0188]
[0189] Example 3
[0190]
[0191] Crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3- Dihydrospiro[indene-2,4'-piperidinyl]-1-amine monosuccinate salt form 1
[0192] Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine free base hemihydrate (Form 1) (Example 2; 8.99 Kg) was suspended in MeOH (500 L) at about 55 to 65°C. Succinic acid (2.52 Kg) dissolved in MeOH (17.8 Kg) was added to the suspension. The solution was stirred at about 55 to 65°C for about 2 to 10 hours, and solids appeared in the solution. The solution was cooled to about 40 to 50°C. Methyl tert-butyl ether ("MTBE", 33.3 Kg) was added dropwise at about 40 to 50°C. After the addition, the mixture was cooled to about 2 to 15°C and stirred at about 2 to 15°C for another 2 hours. The slurry was wet milled for about 25 to 90 minutes at about 2 to 15° C. The slurry was filtered and washed with MTBE (40 Kg) and dried to give crystalline anhydrous (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine monosuccinate salt Form 1 (9.4 Kg, 81% yield, 99.6% purity).
[0193] Powder X-ray diffraction analysis was performed using a Bruker AXSD8 Endeavor diffractometer equipped with a copper (Cu) radiation source. The divergence slit was set to 15 mm with continuous illumination. The diffracted radiation was detected using a PSD-Lynx Eye detector with the detector PSD opening set to 2.99 degrees. The X-ray tube voltage and current were set to 40 kV and 40 mA, respectively. In the θ-θ goniometer, the Cu wavelength was stepped from 3.0 to 40.0 degrees 2θ using a step size of 0.00998 degrees and a step time of 1.0 seconds. Data were collected at 40 °C. The anti-scatter screen was set to a fixed distance of 3.0 mm. The sample was rotated at 15 / min during collection. The sample was prepared by placing it in a low silicon content background sample holder and rotated during collection. Data were collected using Bruker DIFFRAC Plus software and analyzed by EVA diffract plus software. The PXRD data file was not processed before peak search. A preliminary peak assignment was made using the selected peak with a threshold of 1 using the peak search algorithm in the EVA software. To ensure validity, adjustments were made manually; the output of the automatic assignment was visually inspected, and the peak position was adjusted to the peak maximum. Peaks with relative intensity ≥3% were usually selected. Peaks that were not resolved or consistent with noise were usually not selected. The typical error associated with the PXRD peak position specified by USP is at most + / -0.2°2θ (USP-941).
[0194] Example 3, the PXRD pattern of the anhydrous succinate salt of Form 1 is as follows Figure 1 The PXRD peak list (2θ°) and relative intensity data of the compound of Example 3, Form 1 anhydrous succinate salt are provided in Table 6 below:
[0195] Table 6
[0196] Angle (2θ°) ±0.2°2θ Relative strength (%) Angle (2θ°) ±0.2°2θ Relative strength (%) 4.5 85.5 24.4 27.4 8.4 18.3 25.6 3.0 9.0 42.3 26.0 12.1 9.3 44.1 26.2 12.1 12.1 9.3 26.9 10.7 13.9 4.2 28.0 48.4 15.7 20.6 28.3 5.7 16.5 16.9 28.7 7.6 16.6 49.4 29.1 4.1 17.1 10.4 29.9 31.7 17.6 4.8 30.5 9.0 17.8 22.3 31.7 9.2 18.0 6.2 31.8 8.3 18.8 41.2 32.8 6.3 19.7 100.0 33.4 5.3 19.9 14.1 33.8 8.9 21.1 37.5 35.0 10.2 21.3 50.3 35.9 7.6 21.7 21.4 36.1 9.5 21.8 32.6 36.4 4.2 22.8 64.5 36.8 7.0 23.0 10.3 37.1 3.7 23.5 29.4 38.0 8.5 24.0 3.4 38.7 4.9 24.3 75.0 39.3 4.7
[0197] The characteristic PXRD peak list and relative intensity data for the compound of Example 3, Form 1 anhydrous succinate salt (2θ°) are provided in Table 7 below:
[0198] Table 7
[0199]
[0200]
[0201] Solid-state NMR (ssNMR) analysis was performed on a CPMAS probe placed in a Bruker-BioSpin AvanceIII 500 MHz (1H frequency) NMR spectrometer. The material was packaged in a 4 mm ZrO2 rotor. A magic angle spinning rate of 14.0 kHz was used. Spectra were collected at ambient temperature (temperature was not controlled).
[0202] Acquisition using the Proton Decoupled Cross-Polarization Magic Angle Spinning (CPMAS) experiment 13C ssNMR spectra. A phase modulated proton decoupling field of 80-100 kHz was applied during spectral acquisition. The cross-polarization contact time was set to 2 milliseconds and the recycle delay was set to 11.4 seconds ((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine free base (Form 1) hemihydrate crystalline form) or 10.5 seconds (crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate Form 1). The number of scans was adjusted to obtain sufficient signal-to-noise ratio. 13 C chemical shift scaling using 13 CCPMAS experiments were referenced to an external standard of crystalline adamantane, with its upfield resonance set to 29.5 ppm.
[0203] Automated peak picking was performed using Bruker-BioSpin TopSpin version 3.6 software. Typically, a threshold of 5% relative intensity was used for preliminary peak selection. The output of automated peak picking was visually inspected to ensure validity and manual adjustments were made if necessary. Although specific solid-state NMR peaks are reported herein, there does exist a range of these peaks due to differences in instrumentation, samples, and sample preparation. This is common practice in solid-state NMR techniques due to the inherent variability in peak positions. For crystalline solids, 13 The typical variability of the C chemical shift x-axis values is about plus or minus 0.2 ppm. The solid-state NMR peak heights reported herein are relative intensities. The solid-state NMR intensities can vary depending on the actual setup of the CPMAS experimental parameters and the thermal history of the sample.
[0204] Example 3, Form 1 anhydrous succinate 13 C ssNMR spectrum Figure 2 The peaks marked by the hashmark are spinning sidebands. The ssNMR peak list and relative intensity data for the compound of Example 3, Form 1 anhydrous succinate salt are provided in Table 8 below:
[0205] Table 8
[0206]
[0207] Characteristic ssNMR peak list data for the compound of Example 3, Form 1 anhydrous succinate salt are provided in Table 9 below:
[0208] Table 9
[0209]
[0210] Raman spectra were collected using a Thermo Scientific iS50 FT-Raman accessory connected to an FT-IR bench. A CaF2 beam splitter was used in the FT-Raman configuration. The spectrometer was equipped with a 1064 nm diode laser and a room temperature InGaAs detector. Prior to data collection, instrument performance and calibration verification was performed using polystyrene. During data collection, samples in the form of tablets were analyzed in glass NMR tubes or samples were kept static in a suitable sample holder. Spectra were collected using a laser power of 0.1 to 0.5 W and 512 co-accumulated scans. The collection range was 3700 to 100 cm -1 Use 2cm -1 API spectra were recorded at 100 Å resolution and Happ-Genzel apodization was used for all spectra. Multiple spectra were recorded and the reported spectra represent two points.
[0211] Prior to peak picking, the intensity scale was normalized to 1. Peaks were manually determined using Thermo Nicolet Omnic 9.7.46 software. Peak positions were picked at the peak maximum and peaks were only identified when there were slopes on each side; the shoulders of the peaks were not included. For solvent-free crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate salt Form 1, an absolute threshold of 0.06 and a sensitivity of 75 were used during peak picking. Peak positions were rounded to the nearest integer using standard procedures (0.5 round up, 0.4 round down). Peaks with normalized peak intensities between (1-0.75), (0.74-0.30), (0.29-0) were labeled strong, medium, and weak, respectively. Relative peak intensity values are also stated in this report.
[0212] The characteristic peaks of crystalline anhydrous (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine monosuccinate salt Form 1 were selected based on intensity and peak position. Crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 was compared to placebo and active blends (6 and 15% DL) to ensure the uniqueness of crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1.
[0213] Example 3, the complete Raman spectrum of the anhydrous succinate salt of Form 1 is as follows Figure 3 The complete Raman peak list of Example 3, Form 1 anhydrous succinate is provided in Table 10 below:
[0214] Table 10
[0215]
[0216]
[0217] w = weak, peak intensity > 0.30; m = medium, peak intensity 0.31 to 0.74; s = strong, peak intensity < 0.74
[0218] The characteristic Raman peak list data of the compound of Example 3, Form 1 anhydrous succinate salt are provided in Table 11 below:
[0219] Table 11
[0220] <![CDATA[Peak position (cm -1 )]]> Normalized Intensity Classification 1041 0.90 s 1217 0.64 m 1555 0.54 m 1026 0.83 s
[0221] Example 4
[0222] Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydro Spiro[indene-2,4'-piperidinyl]-1-amine phosphate (pattern 1)
[0223] (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine free base (200 mg) was weighed into a 20 mL glass scintillation vial. 90% ethanol / 10% water (5 mL; % v / v) was added to the scintillation vial to form a slurry. Neat phosphoric acid (65.2 μL; 2.1 equiv) was added to the slurry. The slurry was then temperature cycled between ambient temperature and 40°C (4 hour cycle) for 18 hours with stirring. A subsample was isolated by centrifuge filtration. XPRD analysis showed phosphate pattern 1. The remaining slurry was isolated using a Buchner funnel containing Whatmann grade 1 filter paper. The isolated solid was then dried under vacuum at 40°C for approximately 24 hours.
[0224] Example 5
[0225] Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydro Spiro[indene-2,4'-piperidinyl]-1-amine phosphate (pattern 2)
[0226] (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine free base (200 mg) was weighed into a 20 mL glass scintillation vial. 90% ethanol / 10% water (5 mL; % v / v) was added to the scintillation vial to form a slurry. Neat phosphoric acid (32.6 μL; 1.05 equiv) was added to the slurry. The slurry was then temperature cycled between ambient temperature and 40°C (4 hour cycle) for 18 hours with stirring. The solvent was removed using a rotary evaporator. 90% methyl ethyl ketone / 10% water (% v / v) was added to the dried solid to form a slurry. The material was separated using a Buchner funnel containing Whatmann grade 1 filter paper. The separated solid was dried under vacuum at 40°C for approximately 24 hours. This step produces a mixture of Mode 1 and Mode 2 phosphates.
[0227] Example 6
[0228] Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydro Spiro[indene-2,4'-piperidinyl]-1-amine fumarate
[0229] (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine free base (200 mg) was weighed into a 20 mL glass scintillation vial. Acetone (5 mL) was added to the scintillation vial to form a slurry. Neat fumaric acid (55.96 mg; 1.05 equiv) was added to the slurry. The slurry was then temperature cycled between ambient temperature and 40°C (4 hour cycle) for 18 hours with stirring. Centrifugal filtration was used for separation.
[0230] Example 7
[0231] Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydro Spiro[indene-2,4'-piperidinyl]-1-amine tartrate
[0232] (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine free base (200 mg) was weighed into a 20 mL glass scintillation vial. 90% ethanol / 10% water (5 mL; % v / v) was added to the scintillation vial to form a slurry. Neat L-tartaric acid (72.36 mg; 1.05 equiv) was added to the slurry. The slurry was then temperature cycled between ambient temperature and 40°C (4 hour cycle) for 18 hours with stirring. Centrifugal filtration was used for separation.
[0233] Example 8
[0234] Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydro Spiro[indene-2,4'-piperidinyl]-1-amine hydrochloride
[0235] (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine free base (40 mg) was weighed into an HPLC vial. 90% 2-propanol / 10% water (1 mL; % v / v) was added to the vial to form a slurry. Neat hydrochloric acid (16.0 μL; 2.1 equiv) was added to the slurry. The slurry was then temperature cycled between ambient temperature and 40°C (4 hour cycle) with stirring for 96 hours. Centrifugal filtration was used for separation.
[0236] Example 9
[0237] (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro Comparative analysis of the salt forms of [indene-2,4'-piperidinyl]-1-amine
[0238] Solubility
[0239] Solubility was determined by adding 3 mg of compound (Example 2 or Example 3) to 500 μL of the respective appropriate buffer (pH 2 HCl, pH 4 acetate and pH 6 phosphate) (Table 12 and Table 13). After adding the buffer solution, the sample was vortexed. The sample was rotated in an Envirogenie thermomixer at 40° C. for 8 hours, 15° C. for 5 hours and 25° C. for 12 hours. After the thermomixing cycle, the slurry was separated by centrifugal filtration and the separated mother liquor was analyzed by HPLC.
[0240] HPLC method (Table 12 and Table 13): An Agilent 1290UPLC instrument equipped with a Waters XSelect HSS T3 column (100 angstroms, 4.6×150 mm, 5 μm) was used. The column temperature was set to 20° C., the UV wavelength was set to 254 nm, the injection volume was 10 μL, and the flow rate was 1.0 ml / min. 10 mM ammonium acetate adjusted to pH 4.8 was used as mobile phase A, and acetonitrile was used as mobile phase B. The gradient method was set to reach 15% mobile phase B at 0 minutes; reach 95% mobile phase B at 17 minutes and maintain until 22 minutes; reach 15% mobile phase B at 22.1 minutes and maintain until 28 minutes.
[0241] Solubility was determined by adding 20 mg of salt (Example 3 to Example 8) to 3 HPLC vials, adding a magnetic stirring bar and 1 mL of a suitable buffer system (pH 1.2 HCl, pH 4.5 sodium acetate or pH 6.8 phosphate) to each vial (Table 14). The samples were stirred at 37°C for 18 hours. After 24 hours, the slurry was separated by centrifugal filtration and the separated mother liquor was analyzed by HPLC.
[0242] HPLC method (Table 14): A Dionex Ultimate 3000 HPLC instrument equipped with a Waters XSelect HSS T3 column (100 angstroms, 4.6×150 mm, 5 μm) was used. The column temperature was set at 20° C., the UV wavelength was set at 254 nm, the injection volume was 10 μL, and the flow rate was 1.0 ml / min. 10 mM ammonium acetate adjusted to pH 4.8 was used as mobile phase A, and acetonitrile was used as mobile phase B. The gradient method was set to reach 15% mobile phase B at 0 minutes; reach 95% mobile phase B at 17 minutes and hold until 22 minutes; reach 15% mobile phase B at 22.1 minutes and hold until 28 minutes.
[0243] Crystallinity
[0244] Polarized light microscopy ("PLM") was performed using a Leitz Orthoplan optical microscope (Table 12). The samples were dispersed in microscope immersion oil (Type A) on a flat glass substrate with a glass cover. The samples were observed under crossed polarization using a 530 nm wave plate.
[0245] Powder X-ray diffraction ("PXRD") (Table 12) analysis was performed using a Bruker AXSD8 Endeavor diffractometer equipped with a Cu radiation source. The divergence slit was set to 10 mm continuous illumination. The diffracted radiation was detected by a PSD-Lynx Eye detector, and the detector PSD opening was set to 2.99 degrees. The X-ray tube voltage and current were set to 40 kV and 40 mA, respectively. Data were collected at Cu wavelengths from 3.0 to 40.0 degrees 2θ in a θ-θ goniometer using a step size of 0.02 degrees and a step time of 0.3 seconds. The anti-scatter screen was set to a fixed distance of 1.5 mm. The sample was rotated at 15 / min during collection. The sample was prepared by placing the sample in a low silicon content background sample holder and rotated during collection. Data was collected using Bruker DIFFRACPlus software and analyzed by EVA diffract plus software. A divot sample holder was used.
[0246] PLM (Table 13) was performed using less than 1 mg of API material added to a microscope slide, using a drop of high viscosity microscope immersion oil, and applying a cover slip. The slide was then observed under crossed polarization on an Olympus Bx53 polarizing microscope with a 530 nm wave plate. Sample images were collected with an integrated Olympus camera, and photos were taken with Olympus Stream software.
[0247] PXRD (Table 13): Measurement parameters: The Rigaku MiniFlex 6G diffractometer used was equipped with a Cu radiation source. The diffracted radiation was detected by a D / teX Ultra2 detector. The X-ray tube voltage and current were set to 40 kV and 15 mA, respectively. In the Miniflex goniometer, data were collected at Cu wavelengths from 3.0 to 45.0 ° 2θ using a step size of 0.01 ° and a step rate of 3.00 ° / min. The incident slit box was set to 1.25 ° and the length limiting slit was set to 10 mm. The sample was rotated at 10 RPM during collection. The data was analyzed using the Rigaku software SmartLab Studio II. Sample preparation: The sample was prepared by placing in a low silicon content background sample holder (2 mm × 0.5 mm hole). Before measurement, confirm that the sample is flat and filled. The sample was analyzed using the above instrument parameters.
[0248] PLM (Table 14): The presence of crystals was determined using an Olmypus BX50 microscope equipped with a cross-polarized lens and a Motic camera. Images were captured using Motic Images Plus 2.0. All images were recorded using a 20× objective.
[0249] PXRD (Table 14) analysis was performed on a PANalytical X'pert pro with a PIxcel detector (128 channels), scanning the sample between 3 and 35 ° 2θ. The material was gently ground to release any agglomerates and loaded onto a porous disk with a Kapton or Mylar polymer film supporting the sample. The porous disk was then placed in a diffractometer and Cu K radiation (α1 1 2θ) was used running in transmission mode (step size 0.0130 ° 2θ, step time 18.87 seconds) using a 40 kV / 50 mA generator setting. The data were analyzed using the HighScore Plus 4.7 desktop application (PANalytical, 2017) and images were generated.
[0250] stability
[0251] Sample preparation (Table 12): Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine free base hemihydrate (Form 1) - Control: The compound (15.46 mg) was weighed into a 50 mL amber volumetric flask. Methanol (approximately 35 mL) was added to the flask, sonicated for 4 minutes with intermittent stirring, equilibrated to room temperature, made up to volume with methanol and the flask was repeatedly inverted to mix thoroughly. Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine free base hemihydrate (Form 1) - 70°C / 5% relative humidity ("RH") / 1 week: The compound (14.83 mg) was weighed into a 50 mL amber volumetric flask. Methanol (approximately 35 mL) was added to the flask, sonicated for 4 minutes with intermittent stirring, equilibrated to room temperature, made up to volume with methanol and the flask was repeatedly inverted to mix thoroughly. Crystalline (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine free base hemihydrate (Form 1) - 70°C / 75% RH / 1 week: The compound (14.99 mg) was weighed into a 50 mL amber volumetric flask. Methanol (approximately 35 mL) was added to the flask, sonicated for 4 minutes with intermittent stirring, equilibrated to room temperature, made up to volume with methanol and the flask was repeatedly inverted to mix thoroughly.
[0252] Chemical stability (HPLC) (Table 12): A Waters Acquity H-type instrument equipped with a Waters XSelect HSS T3 column (100 angstroms, 4.6×150 mm, 5 μm) was used. The column temperature was set to 20° C., the UV wavelength was set to 254 nm, the injection volume was 10 μL, and the flow rate was 1.0 ml / min. 10 mM ammonium acetate adjusted to pH 4.8 was used as mobile phase A, and acetonitrile was used as mobile phase B. The gradient method was set to reach 15% mobile phase B at 0 minutes; reach 95% mobile phase B at 17 minutes, and maintain until 22 minutes, 15% mobile phase.
[0253] Physical stability (PXRD) (Table 12): Powder X-ray diffraction analysis was performed using a Bruker AXS D8 Endeavor diffractometer equipped with a Cu radiation source. The divergence slit was set to 10 mm continuous illumination. The diffracted radiation was detected by a PSD-Lynx Eye detector with the detector PSD opening set to 2.99 degrees. The X-ray tube voltage and current were set to 40 kV and 40 mA, respectively. Data were collected at Cu wavelengths from 3.0 to 40.0 degrees 2θ in a θ-θ goniometer using a step size of 0.02 degrees and a step time of 0.3 seconds. The anti-scatter screen was set to a fixed distance of 1.5 mm. The sample was rotated at 15 / min during collection. The sample was prepared by placing it in a low silicon content background sample holder and rotated during collection. Data were collected using BrukerDIFFRAC Plus software and analyzed by EVA diffract plus software. A small pit sample holder was used.
[0254] Photostability (Table 12): Sample preparation: Control—Transfer approximately 1 g of sample to a weighing bottle and cover with a glass lid. Wrap the sample with aluminum foil to protect from light and place in a photostability chamber. Photostability Sample: Transfer approximately 1 g of sample to a weighing bottle and then place in a photostability chamber. Storage Conditions: Photostability samples are stored in accordance with ICH photostability option 2: cool white fluorescent lamps designed to produce output similar to that specified in ISO 10977 (1993); near-UV fluorescent lamps having a spectral distribution of 320 nm to 400 nm, and maximum energy emission between 350 nm and 370 nm; a substantial portion of UV should be in the two bands of 320 to 360 nm and 360 to 400 nm. Expose the photostability and dark control samples to a light source providing a light intensity of 5000 ± 500 Lx (near ultraviolet radiation energy 0.84 W / m 2 ±10%) and irradiated for 12 days (the samples were exposed to light providing a total illumination of not less than 1.2 million lux hours and a comprehensive near-UV energy of not less than 200 watt-hours / square meter).
[0255] Photostability (HPLC) (Table 12): Agilent 1100 HPLC equipped with a Waters XSelect HSS T3 column (100 angstroms, 4.6×150 mm, 5 μm) was used. The column temperature was set to 20° C., the UV wavelength was set to 254 nm, the injection volume was 10 μL, and the flow rate was 1.0 ml / min. 10 mM ammonium acetate adjusted to pH 4.8 was used as mobile phase A, and acetonitrile was used as mobile phase B. The gradient method was set to reach 15% mobile phase B at 0 minutes; reach 95% mobile phase B at 17 minutes, and maintain until 22 minutes, 15% mobile phase.
[0256] Sample preparation (Table 13):
[0257] 70°C / 75% RH Sample: Approximately 20 mg of crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate salt Form 1 was placed in an open amber vial in a 70°C / 75% RH chamber.
[0258] 70°C / 5% RH Sample: Approximately 20 mg of crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate salt Form 1 placed in a closed amber vial with the cap taped in a humidity uncontrolled 70°C chamber
[0259] Control sample: approximately 20 mg of crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate salt Form 1 placed in a sealed amber vial in a refrigerator
[0260] Approximately 0.3 mg / mL of each succinate Form 1 sample was prepared by transferring 1 mg of material to an amber vial, adding 3 mL of methanol, and vortexing to dissolve.
[0261] Chemical stability (HPLC) (Table 13): A Waters Acquity UPLC Class I instrument equipped with a Waters XSelect HSS T3 column (100 angstroms, 4.6×150 mm, 5 μm) was used. The column temperature was set to 20° C., the UV wavelength was set to 254 nm, the injection volume was 10 μL, and the flow rate was 1.0 mL / min. Ammonium acetate (10 mM) adjusted to pH 4.8 was used as mobile phase A, and acetonitrile was used as mobile phase B. The gradient method was set to reach 15% mobile phase B at 0 minutes and 95% mobile phase B at 17 minutes; hold until 22 minutes, 15% mobile phase.
[0262] Physical stability (PXRD) (Table 13): A Rigaku MiniFlex 6G diffractometer equipped with a Cu radiation source was used. The diffracted radiation was detected by a D / teX Ultra2 detector. The X-ray tube voltage and current were set to 40 kV and 15 mA, respectively. Data were collected at Cu wavelengths from 3.0 to 45.0° 2θ using a step size of 0.02° and a step rate of 2.00° / min in the Miniflex goniometer. The entrance slit box was set to 1.25° and the length limiting slit was set to 10 mm. The sample was rotated at 10 RPM during collection. Data were analyzed using Rigaku software SmartLab Studio II.
[0263] The samples were prepared by placing in a low silicon background sample holder (0.2 groove plate). Prior to measurement, the samples were confirmed to be flat and filled. The samples were not ground (by mortar and pestle, or by any other means) prior to placement in the sample holder.
[0264] Photostability (Table 13): Crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1 - Photodegradation control (wrapped in foil) 1: Weigh 1.716 mg into a 5 mL volumetric flask, add approximately 3 mL of methanol to the flask, sonicate for 3 minutes with intermittent stirring, equilibrate to room temperature, make up to volume with methanol and repeatedly invert the flask to mix thoroughly.
[0265] 2×ICH photodegradation: Weigh 1.569 mg into a 5 mL volumetric flask, add about 3 mL of methanol to the flask, sonicate for 3 minutes with intermittent stirring, equilibrate to room temperature, make up to volume with methanol and repeatedly invert the flask to mix thoroughly.
[0266] Chemical stability (HPLC) (Table 13): A Waters Acquity H-type instrument equipped with a Waters XSelect HSS T3 column (100 angstroms, 4.6×150 mm, 5 μm) was used. The column temperature was set to 20° C., the UV wavelength was set to 254 nm, the injection volume was 10 μL, and the flow rate was 1.0 mL / min. Ammonium acetate (10 mM) adjusted to pH 4.8 was used as mobile phase A, and acetonitrile was used as mobile phase B. The gradient method was set to reach 15% mobile phase B at 0 minutes and 95% mobile phase B at 17 minutes; hold until 22 minutes, 15% mobile phase.
[0267] Physics (PXRD) (Table 13): Powder X-ray diffraction analysis was performed using a Bruker AXSD8 Endeavor diffractometer equipped with a Cu radiation source. The divergence slit was set to 10 mm continuous illumination. The diffracted radiation was detected by a PSD-Lynx Eye detector with the detector PSD opening set to 2.99 degrees. The X-ray tube voltage and current were set to 40 kV and 40 mA, respectively. Data were collected at a Cu wavelength of 3.0 to 40.0 degrees 2θ in a θ-θ goniometer using a step size of 0.02 degrees and a step time of 0.3 seconds. The anti-scatter screen was set to a fixed distance of 1.5 mm. The sample was rotated at 15 / min during collection. The sample was prepared by placing it in a low silicon background sample holder and rotated during collection. Data were collected using Bruker DIFFRAC Plus software and analyzed by EVA diffract plus software.
[0268] Thermogravimetric analysis ("TGA") (Table 12): Thermogravimetric analysis was performed using a Discovery TGA (TA Instruments) thermogravimetric analyzer. Approximately 10 mg of sample was weighed into an aluminum pan and heated from ambient temperature to 300°C at a heating rate of 10°C / min under a nitrogen purge (10 ml / min for both sample chamber and sky).
[0269] Differential Scanning Calorimetry ("DSC") (Table 12): DSC measurements were performed using a Discovery DSC (TA Instruments) equipped with a refrigerated cooling attachment. All experiments were performed in standard / Tzero aluminum pans. Indium was used to determine the unit cell constant and indium and tin were used as standards for temperature calibration. All measurements were completed under a continuous dry nitrogen purge (50 ml / min). Approximately 1-5 mg of solid sample was weighed into a Tzero aluminum pan, sealed in a non-hermetic manner and heated from 0°C to 250°C at a heating rate of 10°C / min. The experimental data were analyzed using commercially available software (TA Universal Analysis 2000 / Trios software, TA Instruments).
[0270] Dynamic Vapor Sorption ("DVS") (Table 12): A microbalance was calibrated using a 100 mg standard weight. The relative humidity sensor was calibrated using a saturated salt solution at 5.0, 11.3, 32.8, 52.8, 75.3, and 84.3% RH (25°C), and using polyvinylpyrrolidone at 80% RH (25°C). 8-10 mg of powder sample was placed in a platinum sample pan. There was no drying step in this method. RH was first maintained at 30% RH, then reduced to 10% RH, and then reduced to 3% RH, using a standard that continued when the weight change of the sample was <0.001 wt% within 5 minutes or after reaching a maximum equilibrium time of 60 minutes. RH was then gradually increased to 90% in 10% increments, followed by a decrease in 10% RH increments to a final RH of 10%. Similarly, equilibrium was assumed to be reached when the weight change of the sample was <0.001 wt% within 5 minutes or at 120 minutes to the maximum equilibrium time.
[0271] DVS (Table 13): Water sorption and desorption were analyzed using DVS-Resolution. The microbalance was calibrated monthly with a 100 mg standard weight. Approximately 5 mg of API was added to a translucent sample pan and placed in chamber A of the DVS-Resolution. The relative humidity percentage was held at 0% for 1 hour and increased to 90% in 10% increments, then ramped back to 0% in 10% increments. The step was considered complete when a dm / dt change of <0.001% was observed with a step time of a minimum of 30 minutes or a maximum of 120 minutes.
[0272] TGA / DSC (Table 13): A simultaneous DSC / TGA instrument was used for thermal analysis. Approximately 3.2 mg of API was placed in an aluminum TzeroDSC pan and loaded into the instrument via an autosampler. Prior to analysis, the sample was equilibrated to 35°C in the instrument and ramped to 400°C at a ramp rate of 10°C / min. Dry nitrogen from an internal supply was used.
[0273] TGA / DSC (Table 14): About 5-10 mg of material was added to a pre-tared open aluminum pan and loaded into a TA Instruments Discovery SDT 650 auto-synchronous DSC and maintained at room temperature. The sample was then heated from 20°C (ambient temperature) to 400°C at a rate of 10°C / min, during which the change in sample weight and the heat flow response (DSC) were recorded. A flow rate of 200 cm 3 / min nitrogen was used as the sample purge gas.
[0274] DSC (Table 14): About 1-5 mg of material was weighed into an aluminum DSC pan and sealed in a non-hermetic manner with an aluminum lid. The sample pan was then loaded into a TA Instruments Discovery DSC 2500 differential scanning calorimeter equipped with an RC90 cooler. The samples and references were heated to 310°C at a scan rate of 10°C / min and the resulting heat flow response was monitored. The samples were recooled to 20°C and then heated again to 205°C, both at 10°C / min. A flow rate of 50 cm 3 / min nitrogen was used as the purge gas.
[0275] DVS (Table 14): About 10-20 mg of sample was placed in a mesh vapor sorption balance pan and loaded into a DVS Intrinsic dynamic vapor sorption balance by a surface measurement system. At 25°C, the sample was subjected to a ramp curve of 40-90% relative humidity (RH) in 10% increments, and the sample was kept at each step until a stable weight was reached (dm / dt 0.004%, minimum step length 30 minutes, maximum step length 500 minutes). After the adsorption cycle was completed, the sample was dried to 0% RH using the same procedure, and then a second adsorption cycle was performed back to 40% RH. Two cycles were performed. The weight change during the adsorption / desorption cycle was plotted to determine the hygroscopic properties of the sample. Any solid retained was then subjected to XRPD analysis. About 10-20 mg of sample was placed in a mesh vapor sorption balance pan and loaded into a DVS Advantage dynamic vapor sorption balance by a surface measurement system. The samples were subjected to a ramp profile from 40-90% relative humidity (RH) at 25°C in 10% increments, holding the sample at each step until a steady weight was reached (dm / dt 0.004%, minimum step length 30 minutes, maximum step length 500 minutes). After the adsorption cycle was completed, the sample was dried to 0% RH using the same procedure and then subjected to a second adsorption cycle back to 40% RH. Two cycles were performed. The weight change during the adsorption / desorption cycle was plotted to determine the hygroscopic properties of the sample. Any solids retained were then subjected to XRPD analysis.
[0276] NMR (Table 14): NMR experiments were performed on a Bruker AVIIIHD spectrometer equipped with a DCH cryogenic probe, operating at 500.12 MHz for protons. Experiments were performed in deuterated dimethyl sulfoxide ((CD3)2SO) and methanol (CD3OD), and each sample was prepared at approximately 10 mM concentration.
[0277] Table 12 shows the properties of the crystalline free base hemihydrate Form 1 of Example 2. Table 13 shows the properties of the crystalline monosuccinate salt Form 1 of Example 3.
[0278] Table 12
[0279]
[0280] Table 13
[0281]
[0282]
[0283] Table 14 shows comparative data for salts of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine.
[0284] Table 14
[0285]
[0286]
[0287] *PXRD analysis after DVS indicated no polymorphic form change.
[0288] Example 10
[0289] Crystalline anhydrous (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3- Pharmaceutical preparations of dihydrospiro[indene-2,4'-piperidinyl]-1-amine monosuccinate salt form 1
[0290] (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 was formulated to make 10 mg, 25 mg (common mixture 50 mg / g for 10 mg and 25 mg tablets), and 100 mg immediate release tablets. The formulations provided in Tables 15 and 16 consist of microcrystalline cellulose and anhydrous calcium hydrogen phosphate (diluents), crospovidone (disintegrant), and sodium stearyl fumarate (lubricant). (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate salt Form 1 tablet cores were prepared using dry granulation.
[0291] The tablet compositions of the 10 mg and 25 mg tablets prepared using a common mixture of 50 mg / g active ingredients are shown in Table 15, and the tablet composition of the 100 mg tablet is shown in Table 16.
[0292] Table 15
[0293]
[0294] 1 Based on a theoretical potency of 0.789. Amounts may be adjusted based on the potency of the actual drug substance.
[0295] 2 The amount of microcrystalline cellulose can be adjusted to account for slight potency variations in the drug substance to ensure a constant tablet weight.
[0296] NF = National Formulary (United States); Ph Eur = European Pharmacopoeia; JP = Japanese Pharmacopoeia
[0297] Table 16
[0298]
[0299] 1 Based on a theoretical potency of 0.789. Amounts may be adjusted based on the potency of the actual drug substance.
[0300] 2 The amount of microcrystalline cellulose can be adjusted to account for slight potency variations in the drug substance to ensure a constant tablet weight.
[0301] (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate Form 1 immediate release 10, 25 and 100 mg core tablets were prepared using a platform designed and developed for batch dry granulation of solid oral immediate release tablets.
[0302] First, the diluent (part 1 of 2 parts of microcrystalline cellulose) and disintegrant are mixed, followed by the addition of the active ingredient and mixing. The remaining microcrystalline cellulose (part 2 of 2 parts) and the active mixture (previous step) are passed through a co-mill to disaggregate any aggregates. Mixing is then performed to achieve uniformity after grinding. Sodium stearyl fumarate is lubricated to prepare a uniform mixture. The mixture is dry granulated (using roller compression or slugging), and the obtained mass is ground (using an in-line mill or a co-mill). The ground particles are mixed to obtain uniformly distributed granular particles. The particles are lubricated to obtain uniformly lubricated particles. Finally, the uniform mixture is transferred to a tablet press for compression of the tablet core.
[0303] All publications and patent applications cited in this specification are incorporated herein by reference in their entirety.
[0304] All publications and patent applications cited in this specification are incorporated herein by reference in their entirety.It will be apparent to one of ordinary skill in the art that certain changes and modifications may be made to the appended claims without departing from the spirit or scope thereof.
Claims
1. A crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate.
2. The crystalline form of claim 1, characterized by one of the following: 1) a powder X-ray diffraction pattern comprising peaks at the following 2θ values: 19.7, 24.3, 9.3 and 16.6 ± 0.2° 2θ; (2) a Raman spectrum comprising the following wavenumbers: 1041 and 1217 cm -1 ±2cm -1 or (3) 13 The C solid state NMR spectrum contained the following resonance values: 179.0 ppm ± 0.2 ppm.
3. The crystalline form of claim 1 or 2, characterized by two of the following: 1) a powder X-ray diffraction pattern comprising peaks at the following 2θ values: 19.7, 24.3, 9.3 and 16.6 ± 0.2° 2θ; (2) a Raman spectrum comprising the following wavenumbers: 1041 and 1217 cm -1 ±2cm -1 or (3) 13 The C solid state NMR spectrum contained the following resonance values: 179.0 ppm ± 0.2 ppm.
4. The crystalline form according to any one of claims 1 to 3, characterized in that: 1) The powder X-ray diffraction pattern contains peaks at the following 2θ values: 19.7, 24.3, 9.3 and 16.6 ± 0.2° 2θ; (2) The Raman spectrum contains the following wavenumbers: 1041 and 1217 cm -1 ±2cm -1 ; and (3) 13 The C solid state NMR spectrum contained the following resonance values: 179.0 ppm ± 0.2 ppm.
5. The crystalline form of any one of claims 1 to 4, which has a powder X-ray diffraction pattern comprising peaks at the following 2θ values: 19.7, 24.3, 9.3 and 16.6 ± 0.2° 2θ.
6. The crystalline form of any one of claims 1 to 5, which has a powder X-ray diffraction pattern further comprising a peak at the following 2θ value: 9.0 ± 0.2° 2θ.
7. The crystalline form of any one of claims 1 to 6, which has a powder X-ray diffraction pattern further comprising a peak at the following 2θ value: 28.0 ± 0.2° 2θ.
8. The crystalline form of any one of claims 1 to 7, which has a powder X-ray diffraction pattern further comprising a peak at the following 2θ value: 18.8 ± 0.2° 2θ.
9. The crystalline form of any one of claims 1 to 8, which has a powder X-ray diffraction pattern further comprising a peak at the following 2θ value: 15.7 ± 0.2° 2θ.
10. The crystalline form of any one of claims 1 to 9, which has a powder X-ray diffraction pattern further comprising a peak at the following 2θ value: 12.1 ± 0.2° 2θ.
11. The crystalline form of any one of claims 1 to 10, having a Raman spectrum comprising the following wavenumbers (cm -1) value: 1041 and 1217cm -1 ±2cm -1 .
12. The crystalline form of claim 11, which has a Raman spectrum comprising the following wavenumbers (cm -1 ) value: 1026 and 1555cm -1 ±2cm -1 .
13. The crystalline form of any one of claims 1 to 12, 13 The C solid state NMR spectrum contained the following resonance (ppm) values: 179.0 ppm ± 0.2 ppm.
14. The crystalline form of any one of claims 1 to 13, 13 The C solid state NMR spectrum contained the following resonance (ppm) values: 46.4 ppm ± 0.2 ppm.
15. The crystalline form of any one of claims 1 to 14, 13 The C solid state NMR spectrum contained the following resonance (ppm) values: 38.0 ppm ± 0.2 ppm.
16. The crystalline form of any one of claims 1 to 15, 13 The C solid state NMR spectrum contained the following resonance (ppm) values: 141.7 ppm ± 0.2 ppm.
17. The crystalline form of any one of claims 13 to 16, 13 The C solid state NMR spectrum contained the following resonance (ppm) values: 27.1 ppm ± 0.2 ppm.
18. The crystalline form of any one of claims 1 to 17 which is substantially pure and free of alternative forms.
19. A pharmaceutical composition comprising a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine monosuccinate according to any one of claims 1 to 18, and at least one pharmaceutically acceptable excipient.
20. A crystalline form according to any one of claims 1 to 18 for use as a medicament.
21. A method for treating abnormal cell growth in a mammal comprising administering to the mammal a therapeutically effective amount of a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate according to any one of claims 1 to 18.
22. The method of claim 21, wherein the mammal is a human.
23. A crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate according to any one of claims 1 to 18 for use in a method of treating abnormal cell growth.
24. Use of a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate according to any one of claims 1 to 18 for the preparation of a medicament.
25. Use of a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine monosuccinate according to any one of claims 1 to 18 for the preparation of a medicament for treating abnormal cell growth.
26. The method, compound or use according to any one of claims 21, 22, 23 or 24, wherein the abnormal cell growth is cancer.
27. The method, compound or use of claim 26, wherein the cancer is selected from the group consisting of melanoma, juvenile myelomonocytic leukemia, neuroblastoma, Philadelphia chromosome-positive chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, acute myeloid leukemia, myeloproliferative neoplasms (such as polycythemia vera, essential thrombocythemia and primary myelofibrosis), breast cancer, lung cancer, liver cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma, glioblastoma, anaplastic large cell lymphoma, thyroid cancer and spitzoid tumors.
28. The method, compound or use of claim 26, wherein the cancer is selected from the group consisting of non-small cell lung cancer, colon cancer, esophageal cancer, rectal cancer, juvenile myelomonocytic leukemia, breast cancer, melanoma and pancreatic cancer.
29. The method, compound or use of claim 26, wherein the cancer is selected from the group consisting of ALK-positive NSCLC, ROS1-positive NSCLC, BRAF V600E mutant colorectal cancer, RAS mutant solid tumors, NF1 mutant solid tumors, and BRAF3-like mutant solid tumors.
30. The method, compound or use of claim 29, wherein the cancer is ALK-positive NSCLC.
31. The method, compound or use of claim 30, wherein the cancer being treated has been previously treated with lorlatinib and previously treated with platinum-based chemotherapy.
32. The method, compound or use of claim 30, wherein the cancer being treated has been previously treated with lorlatinib and has not been previously treated with platinum-based chemotherapy.
33. The method, compound or use of claim 30, wherein the cancer being treated has not been previously treated with lorlatinib.
34. The method, compound or use of claim 29, wherein the cancer is BRAF V600E mutant colorectal cancer.
35. The method, compound or use of claim 34, wherein the cancer being treated is resistant to treatment with a BRAF inhibitor plus an epidermal growth factor receptor inhibitor.
36. The method, compound or use of claim 34, wherein the cancer being treated is refractory to BRAFi plus EGFRi treatment.
37. The method, compound or use of claim 34, wherein the cancer being treated has not been previously treated with BRAFi plus EGFRi.
38. The method, compound or use of claim 29, wherein the cancer is a RAS mutant solid tumor.
39. The method, compound or use of claim 38, wherein the cancer being treated has been previously treated with standard of care.
40. The method, compound or use of claim 29, wherein the cancer is an NF1 mutant solid tumor.
41. The method, compound or use of claim 40, wherein the cancer being treated has been previously treated with standard of care.
42. The method, compound or use of claim 29, wherein the cancer is a BRAF3 class mutant solid tumor.
43. The method, compound or use of claim 42, wherein the BRAF Class 3 mutation is selected from one or more of the following amino acid substitutions in human BRAF: D287H; P367R; V459L; G466V; G466E; G466A; S467L; G469E; N581S; N581I; D594N; D594G; D594A; D594H; F595L; G596D; G596R and A762E.
44. The method, compound or use of claim 42 or 43, wherein the cancer being treated has been previously treated with standard of care.
45. The method, compound or use of claim 26, wherein the cancer is a KRAS mutant cancer.
46. The method, compound or use of claim 45, wherein the cancer is selected from the group consisting of a KRASG12A mutation, a KRASG12C mutation, a KRASG12D mutation, a KRASG12F mutation, a KRASG12I mutation, a KRASG12L mutation, a KRASG12R mutation, a KRASG12S mutation, a KRASG12V mutation and a KRASG12Y mutation.
47. The method, compound or use of any one of claims 21 to 46, wherein the compound according to any one of claims 1 to 18 is used in combination with an additional therapeutic compound.
48. The method, compound or use of claim 47, wherein the additional therapeutic agent is selected from the group consisting of lorlatinib, binimetinib, cetuximab and encorafenib.
49. The method, compound or use of claim 48, wherein the additional therapeutic compound is lorlatinib.
50. The method, compound or use of claim 48, wherein the additional therapeutic compound is bemetinib.
51. The method, compound or use of claim 48, wherein the additional therapeutic compound is cetuximab and enemafenib.
Citation Information
Patent Citations
Protein tyrosine phosphatase inhibitors
WO2020201991A1
